The Turning Point in Nurse-Patient Centric Blood Collection

Regulatory Framework and Evolution

**FDA Clearance Pathways** — Early mechanical connectors obtained FDA 510(k) clearance as substantially equivalent to Interlink^®, focusing on intended use (reduction of needles) rather than internal design variances⁶. Absent specific standards for reflux or colonization, this facilitated market entry.

**2005 FDA Guidance on Microbial Ingress** — The 2005 FDA guidance for intravascular administration sets recommended microbial ingress testing under simulated repeated use, including bacterial removal post-inoculation⁶. Fluid-filled designs demonstrated superior performance due to disinfectable septa, whereas mechanical valves faced challenges⁷.

**2008 Revisions and Compensatory Measures** — By 2008, the FDA softened verbiage criteria from “bacterial removal” to “prevention of transmission,” permitting non-fluid-filled connectors to meet testing criteria despite evidence of internal colonization⁷. Alcohol-impregnated caps were introduced to mitigate surface contamination⁸, though ineffective against internal growth in long-term use.

**Post-2010 Surveillance** — Following infection outbreaks⁸, a 2010 FDA letter mandated post-market surveillance for positive displacement connectors, redirecting focus to fluid mechanics rather than housing design⁶.

Clinical Implications

Mechanical valves’ plunging mechanics during procedures like Saline-Administer-Saline-Heparin (SASH) can dislodge internalized bacteria⁵, increasing bloodstream infection risks independent of technique. Institutional responses often favored venipuncture³, contributing to vessel depletion and patient morbidity. The 2021 INS Standards cautioned against VAD sampling due to contamination concerns¹, while the 2024 edition mandates weighing venipuncture risks—such as vessel integrity, pain, sample rejection, and hospital-onset bacteremia (HOB)—against VAD use¹,3. This underscores a shift toward competency, emphasizing the importance of nurse assessment and product flexibility to obtain quality blood samples.

Emerging Technologies: The VI ByPass Syringe as a Case Study

Innovations like the VI ByPass Syringe^® (Vascular Integrity, distributed by ICU Medical) exemplify tools addressing these gaps^6-9. This closed-system device incorporates a Sliding Fluid Seal^™ and Velocity Reduction™ flexible technology minimizing manipulation of needle-free connectors, thus helping to reduce microbial contamination⁷. Compatible with any needle-free connector or Y-site, it standardizes aspiration across VAD types, helping to mitigate hemolysis and vessel collapse⁹. Pilot evaluations report excellent nurse usability and alignment with Aseptic Non-Touch Technique (ANTT^®) principles¹0. Such devices facilitate line use, reducing venipuncture frequency and supporting competency-based care.

Discussion

The evolution from compliance post-2000 Act to the 2024 INS competency focus completes a cycle in vascular access. Regulatory detours permitted designs with inherent risks⁴, but until recently guideline updates and technologies for blood collection offered limited corrective pathways. Future research should prioritize prospective trials evaluating nurse-led collection applications and long-term outcomes, including infection rates and vessel integrity^3,9.

Conclusion

Needle-free connectors have transformed vascular access, yet trade-offs have resulted in unresolved issues for more than two decades. The 2024 INS Standards marked a turning point¹, promoting nurse-led, nurse-centric practice considerations. By leveraging adaptable technologies such as the VI ByPass Syringe^®, healthcare systems can minimize risks, enhance patient outcomes, and prioritize nursing competency over compliance.

References

1.Infusion Nurses Society (INS). Infusion Therapy Standards of Practice. 2021.
2.World Health Organization. WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy. Geneva: WHO Press; 2010.
3.Perry C, et al. Comparison of Clinical, Economic, and Humanistic Outcomes Between Direct Venipuncture and VAD-Collected Blood Samples. J Clin Med. 2023;12(20):6471.
4.Chang J, et al. Standards and Practice Guidelines for Venous Blood Specimen Collection. J Lab Med Qual Assur. 2025.
5.Infusion Nurses Society (INS). Infusion Therapy Standards of Practice. 2024 update.
6.Vascular Integrity. Ease-of-Use Pilot Study, University of Iowa. Whitepaper on file, 2021.
7.Vascular Integrity. Microbial Contamination Diversion Study. Whitepaper on file, 2021.
8.Vascular Integrity. Fluid Diversion Validation (Sliding Fluid Seal^™ + Velocity Reduction^™). Whitepaper on file, 2021.
9.Vascular Integrity / Toxikon Labs. Hemolysis Study. Whitepaper on file, 2021.
10.The Association for Safe Aseptic Practice. Product Evaluation of ANTT^® Principles. 2023. On file.